Clinical Trial

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2026 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
Trial Details
NCT Number NCT07450027
Lead Sponsor Elazığ Mental Health and Diseases Hospital
Conditions Methamphetamine Use Disorder, Methamphetamine-induced Psychosis
Enrollment 120 participants
Start Date 2025-09-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04